Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency.
Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other
systemic treatments are generally ignored. To explore alternative treatment options, we
studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma
patients.